Your Momma's Degrassi Blog

Last year, the Food and Drug Administration (FDA) narrowly approved the use of Aduhelm, a new drug from Biogen that the company has priced so highly that it’s expected to drive up the price of Medicare for everyone in America, even those who never need this drug. Aduhelm was the first drug to be approved that fights the accumulation of those "amyloid plaques" in the brain. What makes the approval of the $56,000-a-dose drug so controversial is that while it does decrease plaques, it doesn’t actually slow Alzheimer’s. In fact, clinical trials were suspended in 2019 after the treatment showed “no clinical benefits.” (Which did not keep Biogen from seeking the drug’s approval or pricing it astronomically.)

Over the last two decades, Alzheimer’s drugs have been notable mostly for having a 99% failure rate in human trials. It’s not unusual for drugs that are effective in vitro and in animal models to turn out to be less than successful when used in humans, but Alzheimer’s has a record that makes the batting average in other areas look like Hall of Fame material.

In the face of potential fraud unearthed by Schrag, it's not as of the world has changed overnight.

Four months after Schrag submitted his concerned to the NIH, the NIH turned around and awarded Lesné a five-year grant to study... Alzheimer's. The grants was awarded by Austin Yang, program director at the NIH's National Institute on Aging. Yang also happens to be another of the co-authors on the 2006 paper.

I listed these pendants on my depop :^) thinking of parting with some playboys too